Protocol for the Examination of Specimens From Patients With Carcinoma of the Uterine Cervix

Protocol applies to all invasive carcinomas of the cervix.

Based on AJCC/UICC TNM, 7th edition
Protocol web posting date: December 2013

Procedures
• Excision (Cone/LEEP)
• Radical Trachelectomy
• Radical Hysterectomy
• Pelvic Exenteration

Authors
Alexandra N. Kalof, MD*
Pathology Department, University of Vermont, Burlington, VT
Farnaz Dadmanesh, MD
Pathology Department, Cedars-Sinai Medical Center, Los Angeles, California
Teri A. Longacre, MD
Pathology Department, Stanford University, Stanford, California
Marisa R. Nucci, MD
Pathology Department, Brigham and Women’s Hospital, Boston, Massachusetts
Esther Oliva, MD
Pathology Department, Massachusetts General Hospital, Boston, Massachusetts
Christopher N. Otis, MD, FCAP
Department of Pathology, Baystate Medical Center, Springfield, Massachusetts
Kumarasen Cooper, MBChB, DPhil, FRCPath†
Pathology Department, University of Vermont, Fletcher Allen Health Care, Burlington, Vermont
For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author. † Denotes senior author. All other contributing authors are listed alphabetically.

Previous lead contributors: Philip A. Branton, MD; Robert J. Kurman, MD; Mahul B. Amin, MD
© 2013 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Uterine Cervix Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: UterineCervix 3.2.0.1

Summary of Changes
The following changes have been made since the October 2013 release.

Trachelectomy, Hysterectomy, Pelvic Exenteration

Stromal Invasion
This data element was added, as follows:
Stromal Invasion
Depth: ___ mm
Horizontal extent: ___ mm
___ Extent cannot be assessed

Explanatory Notes

I. Staging
Regional Lymph Nodes: Isolated Tumor Cells
"N1" was changed to “N0(i+)” in the last sentence, as follows:
There is currently no guidance in the literature as to how these patients should be coded (in contrast to similar patients with breast carcinoma); until further studies are available, these patients should be coded as N0(i+), with a comment noting how the cells were identified.

The following changes have been made since the June 2012 release.

Explanatory Notes

I. Staging
TNM Stage Groupings (FIGO 2008) were updated.
Surgical Pathology Cancer Case Summary

Protocol web posting date: December 2013

UTERINE CERVIX: Excision (Cone/LEEP)

Select a single response unless otherwise indicated.

Specimen (select all that apply)
___ Cervix
___ Other (specify): ______________________
___ Not specified

Procedure
___ Cold knife cone excision
___ Loop electrical excision procedure (LEEP) / large loop excision of the transformation zone (LLETZ)
___ Other (specify): ________________________
___ Not specified

Tumor Site (select all that apply) (Notes A, B, C)
___ Left superior quadrant (12 to 3 o’clock)
___ Left inferior quadrant (3 to 6 o’clock)
___ Right inferior quadrant (6 to 9 o’clock)
___ Right superior quadrant (9 to 12 o’clock)
___ Other (specify): ________________________
___ Not specified

Tumor Size
Greatest dimension: ___ cm
Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

Note: all dimensions are important; see definition for “microinvasive carcinoma” under T1a1/IA1

Histologic Type (select all that apply) (Note D)
___ Squamous cell carcinoma
   + ___ Keratinizing
   + ___ Nonkeratinizing
   + ___ Other (specify): ______________________
___ Adenocarcinoma
   ___ Mucinous
      + ___ Endocervical type
      + ___ Intestinal type
      + ___ Other
   ___ Endometrioid
   ___ Clear cell
   ___ Other (specify): ______________________
___ Other (specify): ________________________
___ Carcinoma, type cannot be determined

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Histologic Grade (Note E)
___ Not applicable
___ GX: Cannot be assessed
___ G1: Well differentiated
___ G2: Moderately differentiated
___ G3: Poorly differentiated

Stromal Invasion
Depth: ___ mm
Horizontal extent: ___ mm
___ Extent cannot be assessed

Margins (select all that apply) (Note F)
___ Margins cannot be assessed (eg, obscuring electrocautery artifact)

Endocervical Margin
___ Not involved by invasive carcinoma
   + Distance of invasive carcinoma from margin: ___ mm
   + Specify location, if possible: __________________________
___ Involved by invasive carcinoma
   + Specify location, if possible: __________________________
   + ___ Focal
   + ___ Diffuse
___ Not involved by intraepithelial squamous neoplasia
___ Involved by intraepithelial squamous neoplasia
   + Specify grade: __________________________
___ Not involved by adenocarcinoma in situ
___ Involved by adenocarcinoma in situ

Exocervical Margin
___ Not involved by invasive carcinoma
   + Distance of invasive carcinoma from margin: ___ mm
   + Specify location, if possible: __________________________
___ Involved by invasive carcinoma
   + Specify location, if possible: __________________________
   + ___ Focal
   + ___ Diffuse
___ Not involved by intraepithelial squamous neoplasia
___ Involved by intraepithelial squamous neoplasia
   + Specify grade: __________________________
___ Not involved by adenocarcinoma in situ
___ Involved by adenocarcinoma in situ

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
Deep Margin
___ Not involved by invasive carcinoma
   + Distance of invasive carcinoma from margin: ___ mm
   + Specify location, if possible: ____________________________
___ Involved by invasive carcinoma
   + Specify location, if possible: ____________________________
+ ___ Not involved by intraepithelial squamous neoplasia
+ ___ Involved by intraepithelial squamous neoplasia
   + Specify grade: ____________________________
___ Not involved by adenocarcinoma in situ
___ Involved by adenocarcinoma in situ

Lymph-Vascular Invasion (Note G)
___ Not identified
___ Present
___ Indeterminate

+ Additional Pathologic Findings (select all that apply)
+ ___ None identified
+ ___ Koilocytosis
+ ___ Inflammation
+ ___ Other (specify): ____________________________

+ Comment(s)
Surgical Pathology Cancer Case Summary

Protocol web posting date: December 2013

UTERINE CERVIX: Trachelectomy, Hysterectomy, Pelvic Exenteration

Select a single response unless otherwise indicated.

Specimen (select all that apply) (Note H)
___ Cervix
___ Uterine corpus
___ Right ovary
___ Left ovary
___ Right fallopian tube
___ Left fallopian tube
___ Vagina
___ Urinary bladder
___ Rectum
___ Other (specify): _________________________
___ Not specified

Procedure
___ Trachelectomy
___ Radical hysterectomy
___ Pelvic exenteration
___ Other (specify): _________________________
___ Not specified

Tumor Size
Greatest dimension: ___ cm
+ Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

Tumor Site (select all that apply)
___ Left superior quadrant (12 to 3 o’clock)
___ Left inferior quadrant (3 to 6 o’clock)
___ Right inferior quadrant (6 to 9 o’clock)
___ Right superior quadrant (9 to 12 o’clock)
___ Other (specify): _________________________
___ Not specified

Histologic Type (select all that apply) (Note D)
___ Squamous cell carcinoma
   + ___ Keratinizing
   + ___ Nonkeratinizing
   + ___ Other (specify): _________________________

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
__ Adenocarcinoma
  __ Mucinous
    + ___ Endocervical type
    + ___ Intestinal type
    + ___ Other
  ___ Endometrioid
  ___ Clear cell
    + ___ Other (specify): _________________________
  ___ Other (specify): _________________________
  ___ Carcinoma, type cannot be determined

Histologic Grade (Note E)
  ___ Not applicable
  ___ GX: Cannot be assessed
  ___ G1: Well differentiated
  ___ G2: Moderately differentiated
  ___ G3: Poorly differentiated

Stromal Invasion
  Depth: ___ mm
  Horizontal extent: ___ mm
  ___ Extent cannot be assessed

Margins (select all that apply) (Note F)
  ___ Cannot be assessed
  ___ Margins uninvolved by invasive carcinoma
    Distance of invasive carcinoma from closest margin: ___ mm
    Specify margin, if possible: _________________________
    ___ Carcinoma in situ not identified at distal margin
    ___ Carcinoma in situ present at distal margin
  ___ Margin(s) involved by invasive carcinoma
    Specify margin(s), if possible: _________________________
  ___ Not applicable

Lymph-Vascular Invasion (Note G)
  ___ Not identified
  ___ Present
  ___ Indeterminate

Pathologic Staging (pTNM [FIGO]) (Notes H, I, and J)

TNM Descriptors (required only if applicable) (select all that apply)
  ___ m (multiple primary tumors)
  ___ r (recurrent)
  ___ y (posttreatment)

Primary Tumor (pT)
  ___ pTX [-]: Cannot be assessed
  pT1 [I]: Cervical carcinoma confined to uterus (extension to corpus should be disregarded)
  pT1a [IA]: Invasive carcinoma diagnosed by microscopy only. All macroscopically visible lesions (even with superficial invasion) are pT1b/1B.
  ___ pT1a1 [IA1]: Stromal invasion ≤3.0 mm in depth and horizontal spread ≤7.0 mm

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.
__ pT1a2 [IA2]: Stromal invasion >3.0 mm but not more than 5.0 mm in depth and horizontal spread ≤7.0 mm
__ pT1b [IB]: Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2
__ pT1b1 [IB1]: Clinically visible lesion ≤4.0 cm in greatest dimension
__ pT1b2 [IB2]: Clinically visible lesion >4.0 cm in greatest dimension

pT2 [II]: Tumor invades beyond the uterus but not to pelvic wall or to lower third of vagina
__ pT2a [IIA]: Tumor without parametrial invasion
__ pT2a1 [IIA1]: Clinically visible lesion ≤4.0 cm in greatest dimension
__ pT2a2 [IIA2]: Clinically visible lesion >4.0 cm in greatest dimension
__ pT2b [IIB]: Tumor with parametrial invasion

pT3 [III]: Tumor extends to the pelvic wall and/or involves the lower third of the vagina and/or causes hydronephrosis or non-functioning kidney
__ pT3a [IIIA]: Tumor involves lower third of vagina, but not pelvic wall
__ pT3b [IIIB]: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney
__ pT4 [IVA]: Tumor invades the mucosa of bladder or rectum and/or extends beyond true pelvis (bulleous edema is not sufficient evidence to classify a tumor as pT4)

Regional Lymph Nodes (pN)
__ pNX: Cannot be assessed
__ pN0: No regional lymph node metastasis
__ pN1: Regional lymph node metastasis
__ No nodes submitted or found

Number of Lymph Nodes Examined
Specify: ___
__ Number cannot be determined (explain): __________________________

Number of Lymph Nodes Involved
Specify: ___
__ Number cannot be determined (explain): __________________________

Distant Metastasis (pM)
__ Not applicable
__ pM1 [IVB]: Distant metastasis
    + Specify site(s), if known: __________________________

+ Additional Pathologic Findings (select all that apply)
+ ___ None identified
+ ___ Intraepithelial neoplasia (specify type and grade): __________________________
+ ___ Other (specify): __________________________

+ Ancillary Studies
+ Specify: __________________________

+ Comment(s)
Explanatory Notes

A. Specimen Orientation
If the specimen is the product of a cone biopsy or an excisional biopsy, it is desirable for the surgeon to orient the specimen to facilitate assessment of the resection margins (e.g., stitch at 12 o’clock). The laterality of the specimen is in reference to the patient perspective. Clock values refer to the cervix from the viewer’s perspective (face on). However, specimens frequently are received without orientation. In these cases, the clock face orientation is designated by the pathologist and it is arbitrary.

B. Specimen Handling (Cone/LEEP)
Specimens should have their margins inked and be step-sectioned with orientation by quadrant. For large, unfixed cervical cone/loop electrical excision procedure (LEEP) specimens, the endocervical margin may be marked with ink and pinned on a corkboard with the mucosa facing up. Three hours of fixation before cutting is optimal. The specimen should be sectioned entirely at 1- to 3-mm intervals. Each tissue section may be marked with India ink or a dye such as eosin in order to orient embedding and facilitate evaluation of margins. For optimal evaluation, the sections are placed into separate cassettes, which are numbered consecutively.

C. Absence of Tumor
If no tumor or precursor lesion is present in a cytology or biopsy specimen, the adequacy of the specimen (i.e., its content of both glandular and squamous epithelium) should receive comment. The absence of tumor or precursor lesions in resections must always be documented.

D. Histologic Type
For consistency in reporting, the histologic classification proposed by the World Health Organization (WHO) is recommended; other classification systems may be used, however.

WHO Histologic Classification of Cervical Carcinoma and Precursor Lesions

Epithelial Tumors and Related Lesions
Squamous lesions
Squamous intraepithelial lesions (cervical intraepithelial neoplasia/ squamous intraepithelial lesion [CIN/SIL])
  Mild dysplasia (CIN 1/low-grade squamous intraepithelial lesion [LSIL])
  Moderate dysplasia (CIN 2/high-grade squamous intraepithelial lesion [HSIL])
  Severe dysplasia (CIN 3/HSIL)
  Carcinoma in situ (CIN 3/HSIL)
Early invasive squamous cell carcinoma
Squamous cell carcinoma, not otherwise specified (NOS)
  Keratinizing
  Non-keratinizing
  Basaloid
  Verrucous
  Warty
  Papillary
  Lymphoepithelioma-like
  Squamotransitional
Glandular lesions
   Adenocarcinoma in-situ
   Early invasive adenocarcinoma
   Adenocarcinoma
      Mucinous adenocarcinoma
      Endocervical
      Intestinal
      Signet-ring cell
      Minimal deviation
      Villoglandular
      Endometrioid adenocarcinoma
      Clear cell adenocarcinoma
      Serous adenocarcinoma
      Mesonephric adenocarcinoma

Other epithelial tumors
   Adenosquamous carcinoma
   Glassy cell carcinoma variant
   Adenoid cystic carcinoma
   Adenoid basal carcinoma
   Neuroendocrine tumors
      Carcinoid
      Atypical carcinoid
      Small cell carcinoma
      Large cell neuroendocrine carcinoma
   Undifferentiated carcinoma

E. Histologic Grade
A wide variety of grading systems, including some that evaluate only the extent of cellular differentiation and others that assess additional features such as the appearance of the tumor margin, the extent of inflammatory cell infiltration, and vascular invasion, have been used for squamous cell carcinoma of the cervix. However, there is no consensus emerging from the literature that any of these systems are reproducible or that they provide useful prognostic information. Grading is considered optional at the present time.

For the grading of invasive squamous tumors, it is suggested that 3 grades be used:

Gx Cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated

In contrast to squamous cell carcinoma, most authors who grade cervical adenocarcinoma on the basis of its architecture (glandular and papillary versus solid areas) and its nuclear features have found the grade to have prognostic value.24

G1 Small component of solid growth and mild to moderate nuclear atypia
G2 Intermediate between grades 1 and 3
G3 Solid pattern with severe nuclear atypia

Tumors with no differentiation or minimal differentiation that is discernible only in rare, tiny foci (undifferentiated carcinomas by WHO classification) are categorized as grade 4.
F. Resection Margins
Margins can be involved, negative, or indeterminate for carcinoma. If a margin is involved, whether endocervical, ectocervical, deep, or other, it should be specified. If indeterminate, the reason should be specified (eg, cautery artifact in electroexcision specimens may preclude evaluation of the status of the margin). The severity and extent of a precursor lesion (eg, focal or diffuse) involving a resection margin of a cone should be specified.

If an invasive tumor approximates but does not directly involve a resection margin, the distance between the tumor and the margin should be measured in millimeters. If the tumor involves the uterine corpus, a determination of whether the cervix or corpus is the primary site should be made.

G. Lymph-Vascular Invasion
Many gynecologists feel that the presence of vascular/lymphatic vessel invasion is important because it may change the extent of their surgical treatment. Specifically, the Society of Gynecologic Oncologists (SGO) differs with the Federation of Gynecology and Obstetrics (FIGO) in the definition of early invasive carcinoma. The SGO defines such tumors as being invasive to a depth <3 mm, with a width of <7 mm, but most importantly lacking lymphovascular invasion. At times, it may be difficult to determine whether vascular/lymphatic vessel invasion is present; in such cases, its presence should be categorized as indeterminate. 5

H. Examination of Bladder and Rectum
Currently, pelvic exenterations are rarely seen, but typically when performed indicate advanced tumor stage. In these cases, the extent of tumor involvement of the urinary bladder and rectum and the relation of the tumor to the cervical carcinoma should be described. To evaluate these features, sections of the rectum and bladder should be taken perpendicular to the mucosa directly overlying the tumor in the cervix. A method that provides excellent orientation of the tumor to adjacent structures consists of inflation of the urinary bladder and rectum with formalin and fixation of the specimen for several hours. The entire specimen can then be hemisected through the neoplasm, and appropriate sections can be obtained.

I. Staging
The TNM staging system for cervical cancer endorsed by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC), and the parallel system formulated by the International Federation of Gynecology and Obstetrics (FIGO) are recommended as shown below. 6-8

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

Of note, tumor size has been shown to have prognostic utility for stage I-II lesions, and the most recent 2008 FIGO staging classification has adopted T subclassifications for T2 lesions (cervical carcinoma...
spreading beyond the cervix but not to the pelvic side wall or lower one-third of the vagina), based on tumor size ≤4 cm (T2a1) and >4 cm (T2a2).  

### TNM Classification and FIGO Staging System for Cervical Carcinoma

#### Primary Tumor (T)

<table>
<thead>
<tr>
<th>TNM Category</th>
<th>FIGO Stage</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>(--)</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T1</td>
<td>I</td>
<td>Cervical carcinoma confined to the uterus (extension to the corpus should be disregarded)</td>
</tr>
<tr>
<td>T1a</td>
<td>IA</td>
<td>Invasive carcinoma, diagnosed by microscopy only (all macroscopically visible lesions even those with superficial invasion are pT1b/stage IB) *</td>
</tr>
<tr>
<td>T1a1</td>
<td>IA1</td>
<td>Measured stromal invasion 3.0 mm or less in depth## and 7.0 mm or less in horizontal spread</td>
</tr>
<tr>
<td>T1a2</td>
<td>IA2</td>
<td>Measured stromal invasion more than 3.0 mm in depth## and not more than 5.0 mm## with a horizontal spread 7.0 mm or less</td>
</tr>
<tr>
<td>T1b</td>
<td>IB</td>
<td>Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2</td>
</tr>
<tr>
<td>T1b1</td>
<td>IB1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1b2</td>
<td>IB2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2</td>
<td>II</td>
<td>Tumor invades beyond the uterus but not to pelvic wall or to lower third of vagina</td>
</tr>
<tr>
<td>T2a</td>
<td>IIA</td>
<td>Tumor without parametrial invasion</td>
</tr>
<tr>
<td>T2a1</td>
<td>IIA1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T2a2</td>
<td>IIA2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2b</td>
<td>IIB</td>
<td>Tumor with parametrial invasion</td>
</tr>
<tr>
<td>T3</td>
<td>III</td>
<td>Tumor extends to the pelvic wall and/or involves the lower third of the vagina, and/or causes hydronephrosis or non-functioning kidney</td>
</tr>
<tr>
<td>T3a</td>
<td>IIIA</td>
<td>Tumor involves lower third of vagina, no extension to pelvic wall</td>
</tr>
<tr>
<td>T3b</td>
<td>IIIB</td>
<td>Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney</td>
</tr>
<tr>
<td>T4###</td>
<td>IVA</td>
<td>Tumor invades the mucosa of bladder or rectum and/or extends beyond true pelvis###</td>
</tr>
<tr>
<td>M1</td>
<td>IVB</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

* The current FIGO staging omits specific reference to glandular lesions in stage IA.  

** The depth of invasion is measured from the base of the epithelium, either surface or glandular, from which it originates. Endocervical adenocarcinoma should be measured from the epithelial stromal interface to the deepest point of invasion. Vascular space involvement, either venous or lymphatic, does not alter the staging.  

### Regional Lymph Nodes (N) * (TNM Staging System)

| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Regional lymph node metastasis |

### Presence of bullous edema is not sufficient evidence to classify a tumor as T4. The lesion should be confirmed by biopsy.
*Regional lymph nodes include paracervical, parametrial, hypogastric (obturator); common, internal and external iliac; presacral and sacral nodes. Metastasis to lymph nodes outside of the regional nodal group is classified as distant metastasis.

**Distant Metastasis (M) (TNM Staging System)**

| M0 | No distant metastasis |
| M1 | Distant metastasis (including peritoneal spread, involvement of supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver or bone)* |

* Classified as stage IVB in the FIGO staging system.

**TNM Stage Groupings (FIGO 2008)**

| Stage 0* | Tis | N0 | M0 |
| Stage I | T1 | N0 | M0 |
| Stage IA | T1a | N0 | M0 |
| Stage IA1 | T1a1 | N0 | M0 |
| Stage IA2 | T1a2 | N0 | M0 |
| Stage IB | T1b | N0 | M0 |
| Stage IB1 | T1b1 | N0 | M0 |
| Stage IB2 | T1b2 | N0 | M0 |
| Stage II | T2 | N0 | M0 |
| Stage IIA | T2a | N0 | M0 |
| Stage IIA1 | T2a1 | N0 | M0 |
| Stage IIA2 | T2a2 | N0 | M0 |
| Stage IIB | T2b | N0 | M0 |
| Stage III | T3 | N0 | M0 |
| Stage IIIA | T3a | N0 | M0 |
| Stage IIIB | T3b | Any N | M0 |
| | | T1 - 3 | N1 | M0 |
| Stage IVA | T4 | Any N | M0 |
| Stage IVB | Any T | Any N | M1 |

*Note: FIGO no longer includes Stage 0 (Tis).

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

**The “m” suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.
Additional Descriptors

Residual Tumor (R)
Tumor remaining in a patient after therapy with curative intent (e.g., surgical resection for cure) is categorized by a system known as R classification, shown below.

RX: Presence of residual tumor cannot be assessed
R0: No residual tumor
R1: Microscopic residual tumor
R2: Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

Lymph-Vascular Invasion (LVI)
LVI indicates whether microscopic lymph-vascular invasion is identified. LVI includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

Regional Lymph Nodes: Isolated Tumor Cells
Isolated tumor cells (ITC) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITC found by either immunohistochemical (e.g., cytokeratin) examination or non-morphological/molecular techniques (e.g., flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be so identified.10 There is currently no guidance in the literature as to how these patients should be coded (in contrast to similar patients with breast carcinoma); until further studies are available, these patients should be coded as N0(i+), with a comment noting how the cells were identified.

L. Examination of Parametria
The parametria may be measured grossly, but their width varies according to the elasticity of the tissue. Careful microscopic examination of the parametria is important for evaluation of the lateral margins and/or soft tissue extension.

K. Cytology Diagnosis
The updated Bethesda System of cytologic classification11 is strongly recommended for consistency in reporting of Papanicolaou smears and is shown below. Although other classification systems may be used, the Papanicolaou class designation system is archaic and not recommended. The Bethesda System has been adopted by most cytology and pathology organizations for the classification of cytologic specimens from the female genital tract. According to this system, the terms “low-grade squamous intraepithelial lesion” (LSIL) and “high-grade squamous intraepithelial lesion” (HSIL) are used to encompass the spectrum of intraepithelial lesions otherwise classified as dysplasia/cervical intraepithelial neoplasia (CIN). Cellular changes characteristic of human papilloma virus (HPV), mild dysplasia, and a combination of both are classified as LSIL; and moderate (CIN 2) and severe dysplasia-carcinoma in situ (CIN 3) are classified as HSIL.
The Bethesda System 2001 Cervical/Vaginal Classification

Negative for Intraepithelial Lesion or Malignancy

Organisms
- *Trichomonas vaginalis*
- Fungal organisms morphologically consistent with *Candida* spp
- Shift in flora suggestive of bacterial vaginosis
- Bacteria morphologically consistent with *Actinomyces* spp
- Cellular changes associated with Herpes simplex virus

Other non-neoplastic findings (optional to report, list not inclusive)
- Reactive cellular changes associated with
  - inflammation (includes typical repair)
  - Intrauterine contraceptive device (IUD)
  - irradiation
- Glandular cells status post hysterectomy
- Atrophy

Other
- Endometrial cells (in a woman greater than or equal to 40 years of age; specify if “negative for squamous intraepithelial lesion”)

Epithelial Cell Abnormalities

Squamous Cell
- Atypical squamous cells (ASC)
  - of undetermined significance (ASC-US)
  - cannot exclude HSIL (ASC-H)
- Low-grade squamous intraepithelial lesion (LSIL)
  - encompassing: HPV/mild dysplasia/CIN I
- High-grade squamous intraepithelial lesion (HSIL)
  - encompassing: moderate and severe dysplasia/ CIN2/CIN3/carcinoma in situ (CIS)
  - with features suspicious for invasion (if invasion suspected)
- Squamous cell carcinoma

Glandular Cell
- Atypical
  - endocervical cells (NOS or specify in comment)
  - endometrial cells (NOS or specify in comment)
  - glandular cells (NOS or specify in comment)
- Atypical
  - endocervical cells, favor neoplastic
  - glandular cells, favor neoplastic
- Endocervical Adenocarcinoma in situ (AIS)
- Adenocarcinoma
  - endocervical
  - endometrial
  - extrauterine
  - not otherwise specified (NOS)

Other Malignant Neoplasms
- Specify
L. Special Studies

HPV Testing
Human papillomaviruses are uniformly accepted to play an etiologic role in cervical carcinogenesis and are detectable in greater than 90% of preinvasive and invasive cervical epithelial neoplasms, with HPV types 16 and 18 being the most frequent types associated with invasive carcinoma. While HPV genotyping assays to determine specific high-risk HPV type(s) have not yet become standard practice, the most recent 2006 consensus guidelines published through the American Society for Colposcopy and Cervical Pathology (ASCCP) have expanded the clinical indications for HPV testing. Based on large screening studies showing an improved sensitivity and negative predictive value of high-risk HPV testing in combination with cytology, the ASCCP is currently recommending the use of molecular testing for high-risk subtypes of HPV together with cervical cytology for screening in women 30 years of age and older. Women who are negative on both tests can defer further screening for 3 years. Women who are positive for high-risk HPV DNA but show no evidence of dysplasia on cytology or colposcopic biopsy remain a particular management conundrum. Since the majority of HPV-positive women, even those 30 years and older, will clear the infection and become HPV negative on re-screening, the current consensus guidelines recommend conservative follow-up for the HPV-positive, cytology-negative patients, with repeat cytology and HPV testing at 12-month intervals. Persistent high-risk HPV positivity at subsequent re-screening then warrants colposcopy.

p16 Immunohistochemistry
Immunohistochemistry has served as an important adjunct to the histologic diagnosis of CIN in difficult lesions, with p16 immunoreactivity being a good surrogate marker for high-risk HPV infection. p16 immunostaining in the squamous epithelium, however, should be diffuse; strong nuclear and cytoplasmic staining, as focal strong p16 reactivity, may be identified not only in dysplastic squamous epithelium but also in benign squamous epithelium (Table 1). p16 immunostaining is also considered a better candidate (rather than HPV in situ hybridization) for the initial assessment of cervical biopsies that are histologically indeterminate for dysplasia given its wide availability, easy interpretation, and high sensitivity and specificity. Given the heterogenous staining patterns seen in low-grade CIN lesions, however, immunohistochemistry for p16 is generally reserved for lesions that are morphologically suspicious or indeterminate for high-grade dysplasia. ProEx C, an immunohistochemical assay targeting both topoisomerase II-alpha and minichromosome maintenance protein-2 (MMP-2), has recently been shown to have high sensitivity and specificity for HPV-associated lesions of the cervix, with similar staining patterns as those seen for p16 and MIB-1 (Ki-67).

Immunohistochemistry: Endocervical versus Endometrial Adenocarcinoma
Immunohistochemistry can also be helpful in the differential diagnosis between endocervical and endometrial carcinoma, especially in curettage specimens, as endometrial carcinomas may show mucinous differentiation. A panel of antibodies, rather than one antibody, is most useful; in most instances this includes vimentin, ER, p16 and monoclonal CEA.
Table 1. p16 Immunohistochemistry in the Differential Diagnosis of Squamous and Glandular Lesions of the Uterine Cervix

<table>
<thead>
<tr>
<th></th>
<th>p16*</th>
<th>MIB-1 (Ki-67)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSIL (CIN I)</td>
<td>+/-</td>
<td>increased</td>
</tr>
<tr>
<td>HSIL (CIN II-III)</td>
<td>+</td>
<td>increased (full thickness)</td>
</tr>
<tr>
<td>AIS</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>AIM</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>Reactive squamous or glandular atypia</td>
<td>+/-</td>
<td>+</td>
</tr>
<tr>
<td>Tubal metaplasia</td>
<td>+/-</td>
<td>-</td>
</tr>
</tbody>
</table>

LSIL, low-grade squamous intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial neoplasia; CIN, cervical intraepithelial neoplasia; AIS, adenocarcinoma in situ; AIM, atypical immature metaplasia.

*p16 expression (nuclear and cytoplasmic) is a surrogate marker of high-risk HPV (eg, HPV 16, 18). In LSIL, the p16 expression may be confined to the lower one-third/lower one-half of the squamous epithelium or show focal immunoreactivity (the latter being a pattern of expression, albeit cytoplasmic only, that may also be seen in reactive squamous epithelia). HSIL p16 immunoreexpression usually involves two-thirds or full thickness of the squamous epithelium. Despite these generalizations, the pattern of p16 expression should not be used to stratify dysplastic squamous intraepithelial lesions into LSIL versus HSIL; this distinction should be made on the basis of standard histologic criteria.

References


